Unknown PHASE1 INTERVENTIONAL 3-arm NCT04841720

A Study Evaluating Drug-Drug Interaction (DDI) Between HSK16149 Capsules and Metformin Hydrochloride Tablets

Phase I Clinical Study to Evaluate the Drug-drug Interaction Between HSK16149 Capsules and Metformin Hydrochloride Tablets in Healthy Subjects

Sponsor: Haisco Pharmaceutical Group Co., Ltd.

Conditions Diabetic Neuropathies Diabetic Neuropathy Peripheral

Interventions HSK16149 HSK16149+Metformin（phase 3） Metformin Hydrochloride tablet

Updated 5 times since 2021 Last updated: Apr 8, 2021 Started: Apr 1, 2021 Primary completion: Jun 30, 2021 Completion: Aug 15, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04841720, this PHASE1 trial focuses on Diabetic Neuropathies and Diabetic Neuropathy Peripheral and remains ongoing. Sponsored by Haisco Pharmaceutical Group Co., Ltd., it has been updated 5 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Oct 2024 — Present [monthly]

Unknown PHASE1
Sep 2024 — Oct 2024 [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
May 2023 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
May 2021 — May 2023 [monthly]

Recruiting PHASE1

First recorded

Apr 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Haisco Pharmaceutical Group Co., Ltd.
Hebei Medical University Fourth Hospital

Data source: Haisco Pharmaceutical Group Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shijiazhuang, China